Eighteen Days Into a Thirty-Day Supply: A Kansas Oxycodone Judgment Call
Amara is the staff pharmacist at a Wichita community pharmacy. On a Friday evening she receives an electronic prescription for oxycodone/acetaminophen 10/325 mg, quantity 90, one tablet every eight hours as needed, no refills. The prescriber is a family physician whose office is in Kansas City, Missouri; the visit was a video call and the two have never met in person. The patient, a 34-year-old Kansas resident, wants the full 90 tablets and will pay cash because "insurance is being difficult." Her profile shows her last oxycodone fill 18 days ago, a 30-day supply, at a different pharmacy. A K-TRACS query shows 240 oxycodone tablets and four different prescribers in the past 90 days, plus an active alprazolam prescription from a fifth prescriber. The prescriber's office closed at 5 p.m. and will not reopen until Monday. The patient says she flies to Denver tomorrow and "cannot travel without it."
1. What must Amara verify before she decides, and which objective findings are the strongest red flags?
Read the worked answer
Verify first, decide second. Before any early-fill analysis, Amara needs facts she can document.
- Prescriber authority. Confirm the physician holds an active license and a DEA registration covering the schedule and the location of practice, and that a video-only encounter satisfies the DEA telemedicine rule in force on the date of dispensing. A video relationship is not automatically invalid, but it must fit a current federal flexibility or exception, and the pharmacist should note which one.
- K-TRACS and the patient profile. Kansas requires dispensers to report controlled substance dispensing to K-TRACS; reviewing it before a high-risk fill is how a pharmacist exercises the corresponding responsibility that 21 CFR 1306.04(a) places on both prescriber and dispenser.
The strongest red flags are objective and cumulative, never a single item: cash payment, a fill 18 days into a 30-day supply, 240 oxycodone tablets plus four prescribers and an overlapping benzodiazepine in 90 days, an out-of-state prescriber with no in-person exam, and a deadline narrative ("I fly tomorrow"). Each has an innocent explanation; together they obligate the pharmacist to resolve them before filling, and to write down what she checked.
2. Can she dispense the full 90 tablets tonight? Explain the early-fill and partial-fill rules that apply.
Read the worked answer
No rule compels her to fill, and no rule gives the patient a right to an early fill. Schedule II prescriptions cannot be refilled, so this is a new order, not a renewal.
An early fill is not categorically illegal. If the prescriber documents a legitimate medical explanation - a dose increase, a lost or stolen supply supported by a police report, documented travel with a need for extra doses - the pharmacist may fill early and should record the reason. Here the only explanation is travel, which is convenience rather than medical necessity, and it cannot be verified because the office is closed.
Partial filling is available only when the patient or the prescriber requests it. Under DEA rules, a Schedule II prescription may be partially filled at the request of the patient or prescriber, with the remainder dispensed within 30 days of the date written, and the pharmacist must note the quantity dispensed on the prescription. Amara cannot impose a partial fill on her own to split the difference, and she cannot hold the electronic prescription hostage. Cash payment and insurance problems change none of this analysis.
3. She decides not to fill. What must she do and say, and what must she avoid?
Read the worked answer
Declining is lawful when red flags remain unresolved after a reasonable, documented effort. The record should show what she checked (K-TRACS, the profile, prescriber verification), what she attempted (calls to the prescriber and to prior pharmacies), and precisely what stayed unresolved.
She should tell the patient plainly that she cannot fill today, without accusing her of drug-seeking, and explain that the prescriber will be contacted Monday. She should not confiscate the prescription or refuse to return it; the patient remains free to have it filled elsewhere, and Amara should cooperate if a transfer is requested.
Three errors to avoid. First, disclosing more of the patient's health information to other pharmacies than treatment requires. Second, annotating a record with speculation instead of facts. Third, treating her refusal as the end of the matter: a call to the prescriber Monday, plus a note that K-TRACS was reviewed, protects both the patient and the license. If the pattern repeats across pharmacies, notifying the prescriber and, where warranted, the Board or DEA is a separate, later decision.